DIAGNOS inc.

DIAGNOS inc.

0.32
CAD
-0.01
(-4.55%)
-0.04EPS
33.11MMarket Cap
Dec 01Next Earn
DIAGNOS inc.
TSXV:ADK
(TSX Venture Exchange)

Recent

price

0.32

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
CAD
0.21
0.21
0.23
0.35
0.06
0.09
0.19
0.1
0.02
0.01
- -
0.01
0.01
- -
- -
- -
- -
Revenue per Share
-0.25
-0.35
-0.31
-0.21
-0.29
-0.3
-0.24
-0.17
-0.2
-0.08
-0.03
-0.04
-0.04
-0.04
-0.05
-0.04
-0.04
Basic EPS, GAAP
-0.3
-0.32
-0.32
-0.16
-0.28
-0.23
-0.17
-0.15
-0.13
-0.07
-0.02
-0.03
-0.03
-0.03
-0.04
-0.03
-0.03
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
0.23
0.37
0.22
0.04
-0.02
-0.3
-0.2
-0.21
-0.24
0.03
0.02
- -
-0.03
-0.04
- -
0.01
0.01
Book Value per Share
0.22
0.36
0.22
0.04
-0.02
-0.3
-0.2
-0.21
-0.24
0.03
0.02
- -
-0.03
-0.04
- -
0.01
0.01
Tangible Book Value per Share
5
6
7
8
10
11
12
17
19
41
63
69
70
73
88
108
110
Basic Weighted Avg Shares
1
1
2
3
1
1
2
2
- -
- -
- -
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
-150
-144.92
-136.23
-60.85
-472.94
-277.46
-82.6
-152.94
-897.47
-843.5
-854.98
-605.36
-457.37
-1,522.53
-3,671.68
-6,490.62
-6,459.65
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
-1
-2
-2
-2
-3
-3
-3
-3
-4
-3
-2
-3
-2
-3
-4
-5
-5
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-121.68
-165.16
-135.44
-60.66
-501.19
-325.27
-122.57
-179.63
-1,175.93
-1,020.42
-768.07
-594.35
-510.72
-1,833.93
-4,129.65
-6,956.84
-6,956.84
Profit Margin (%)
1
2
2
1
- -
-1
-2
- -
-1
2
1
1
- -
-1
- -
1
1
Working Capital
- -
- -
- -
1
- -
2
2
4
4
- -
- -
1
2
2
- -
- -
- -
LT Debt
1
2
2
- -
- -
-3
-3
-4
-5
2
1
- -
-2
-3
- -
1
1
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
-82.64
-124.4
-99.95
-156.8
- -
- -
- -
- -
- -
- -
-139.01
- -
- -
- -
- -
-990.25
-990.25
Return on Common Equity (%)

Capital Structure

CAD

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
ST Debt
2
2
1
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
102
119
120
Market Capitalization
29
45
33

Working Capital

CAD

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
Total Current Assets
1
4
2
Cash, Cash Equivalents & STI
1
3
2
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
2
2
1
Payables & Accruals
- -
1
- -
ST Debt
2
2
1
Deferred Revenue
- -
- -
- -

Growth Rates

CAD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
153.35%
330%
194.67%
Free Cash Flow
9.14%
25.1%
3.11%
Net Income, GAAP
6.36%
18.34%
6.27%
Sales/Revenue/Turnover
-5.26%
-13.18%
-36.92%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

CAD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

CAD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.01
-0.01
-0.01
-0.01
-0.04
2025
-0.01
-0.01
-0.01
-0.01
-0.05
2026
-0.01
-0.01
-0.01
-0.01
-0.04

Quarterly Dividends Per Share

CAD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Business
DIAGNOS Inc. is a medical diagnostics company specializing in the development and commercialization of non-invasive diagnostic imaging products and services. Its core offerings include advanced medical diagnostic solutions that utilize proprietary technologies to provide early detection and monitoring of diseases, particularly cancer. The company’s product portfolio features diagnostic imaging systems designed to enhance the accuracy and efficiency of disease diagnosis and treatment evaluation. DIAGNOS operates primarily in North America, focusing on healthcare providers, hospitals, and medical research institutions. Founded in 2003 and headquartered in Quebec, Canada, DIAGNOS Inc. has established itself in the healthcare and medical diagnostics industry through innovations in technology-driven diagnostic tools. Recently, the company has expanded its strategic footprint by entering into new partnerships aimed at enhancing its diagnostic capabilities and broadening its market reach. It has also launched new diagnostic products that leverage artificial intelligence and advanced imaging techniques to improve clinical outcomes. These developments reflect DIAGNOS's commitment to expanding its technology offerings and strengthening its presence in the medical diagnostics market. DIAGNOS Inc. continues to serve customers with a comprehensive suite of diagnostic imaging solutions and services, including product development, manufacturing, sales, and technical support. Its research and development efforts focus on advancing diagnostic accuracy and patient care while expanding applications of its technologies across various medical conditions beyond oncology. The company remains headquartered in Quebec and operates through subsidiaries and collaborations within the healthcare sector to maintain its competitive edge and drive growth in innovation-oriented medical diagnostics.

Company News

  • DIAGNOS Provides an Update on Stock Warrants

  • DIAGNOS Advances Regulatory Strategy with US FDA Submission for CARA System

  • DIAGNOS to Hold its Annual General Meeting of Shareholders on September 30, 2026

  • DIAGNOS Receives Saudi FDA Medical Device License for CARA System, Bringing AI-Assisted Retinal Image Analysis to Saudi Arabia

  • DIAGNOS Receives Health Canada Medical Device Licence for CARA System, Bringing AI-Assisted Retinal Image Analysis to Canadian Optometrists

  • DIAGNOS to Extend the Exercise Period of Stock Warrants

  • Emerging Growth Research Releases Flash Report on DIAGNOS, Highlighting Regulatory Catalysts and Commercialization Potential for CARA AI Platform

  • DIAGNOS to Present at the Emerging Growth Conference on June 10, 2026

  • DIAGNOS Announces Amendment to Convertible Debentures

  • DIAGNOS Provides an Update on Sales and Regulatory Activities for CARA

  • DIAGNOS Successfully Completes the Renewal of US-FDA Medical Device Establishment Registration

  • DIAGNOS (OTCMKTS:DGNOF) Trading Up 2.6% – Time to Buy?

  • DIAGNOS Announces Amendments to Convertible Debentures and Stock Warrants

  • DIAGNOS to present at Centurion One Capital 9th Annual Toronto Growth Conference

  • DIAGNOS (OTCMKTS:DGNOF) Trading 1.6% Higher – Still a Buy?

  • DIAGNOS and ÉTS Announce $1M+ Federal Investment to Propel Next-Generation Retinal AI Innovation

  • DIAGNOS Announces the Engagement of IBN

  • Head to Head Analysis: DIAGNOS (OTCMKTS:DGNOF) vs. Fathom (NASDAQ:FTHM)

  • Diagnos Announces Closing of Oversubscribed $4 Million Brokered Private Placement Led by Centurion One Capital

  • Contrasting DIAGNOS (OTCMKTS:DGNOF) & Priority Technology (NASDAQ:PRTH)